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The opportunity of a screening for lung cancer has been
debated for years, since the value of low-dose spiral CT
in detecting small parenchymal lesions was demonstrated
by ELCAP and other reports. I would like to present
to ICIS members the first results of a preliminary study
performed in Milan, even though complete data cannot
be divulged prior to publication. These results could help
in planning further studies or new protocols.
The study started in May 2000. 1036 volunteers, over
50 years of age, were enrolled who were either heavy
smokers or ex-smokers with a history of more than 1
packet/day for more than 20 years. They have all been
submitted to two yearly consecutive low-dose spiral CT
chest examination (140 kVp, 40 mA, 2 : 1 pitch, with a
slice thickness of 10 mm. Effective dose equivalent to
patient was estimated 0.7 mSv).
The examined population had a mean age of 58 (range
50–70), 742 males and 297 females, smoking on average
26 cigarettes a day for a mean of 37 years. 14% of
volunteers had stopped smoking for a mean of 9 years.
After the first low-dose CT, 5.91% of volunteers were
recalled for further investigations, as a pulmonary lesion
greater than 5 mm was detected. Nodules smaller than
5 mm were not considered for diagnostic work-up: at
the second year CT only 1/151 of such nodules showed
increased size (from 4.8 to 7.5 mm). This was an
adenocarcinoma (T1N0).
Out of the 61 recalled subjects, 15 had non-nodular
abnormalities and 46 a non-calcified nodular lesion.
Diagnostic work-up was performed by HRCT, contrast
enhancement evaluation (feasible in 65% of nodules,
having positive basal density and homogeneous enhance-
ment), PET (for lesions greater than 7 mm), 3 months’
follow-up with volumetric analysis and biopsy when
necessary.
With regard to non-nodular lesions, HRCT, PET scan
and follow-up (required in 5/15 cases) showed to be the
most useful and accurate methods to reach the diagnosis.
In one case only a VAT biopsy was performed on a benign
lesion (a growing partially solid lesion, positive to PET
scan, that proved to be due to post-inflammatory changes
due to bronchiectasis).
The definitive diagnosis of non-calcified nodules was
reached in 58% of cases on the basis of HRCT
morphology and evaluation of nodular density (when
lower than 0 H.U; considered benign): no benign case
was biopsied or subjected to surgery; a false-negative
diagnosis was due to a small apical nodule, diagnosed
as a scar, but the lesion increased from 8 to 15 mm in
diameter at the second year low-dose CT. This was a
T1N0 adenocarcinoma.
The results of contrast enhancement and PET agreed
in 22% of cases, leading to diagnosis: we had two false-
positive diagnoses (an intraparenchymal inflammatory
node and a MALT lymphoma) and one false-negative (an
adenocarcinoma diagnosed 3 months later on the basis
of its growth, evaluated at HRCT due to its irregular
morphology).
Follow-up for evaluation of nodule growth was
required to reach a diagnosis in 22% of recalled patients:
all the diagnoses, but one, were confirmed by operation
(in malignant cases) or by the 1 year follow-up. Only one
case of a regular round and smooth 8 mm nodule, with
indeterminate contrast enhancement and PET negative,
grew from 3.42 to 5.25 mm3 in 6 months and was
submitted to VAT biopsy. This was a hamartoma.
Only 7% of the recalled patients with benign lesions
were submitted to invasive procedures.
Preliminary results confirm the ability of low-dose
CT to detect small parenchymal lesions. The recall
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rate is low, considering that only nodules greater than
5 mm are submitted to follow-up, and this seems
to be justified by our results. The use of contrast
enhancement and PET scan to characterize the lesions
reduces the need of follow-up and of invasive proce-
dures.
